| abstract |
The problem of the present invention is to provide a compound having a GR selective binding activity, which shows less action on other nuclear receptors such as progesterone receptor (PR), mineralocorticoid receptor (MR) and the like. The present invention provides a condensed tetrahydroquinoline compound represented by the following formula (I) n n n n n n n n n n wherein each symbol is as defined in the present specification, or a pharmaceutically acceptable salt thereof or a hydrate thereof. |